Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Frequently asked questions
What sector does Atossa Therapeutics, Inc (ATOS) operate in?
Atossa Therapeutics, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Atossa Therapeutics, Inc (ATOS) current stock price?
As of the latest data, Atossa Therapeutics, Inc stock price is $2.64, with a previous close of $2.79. Atossa Therapeutics, Inc lost -$0.15 in the last trading session, representing a -5.38% loss.
What is Atossa Therapeutics, Inc (ATOS) current market capitalization?
Atossa Therapeutics, Inc market cap is approximately 26.35 million.
What is Atossa Therapeutics, Inc (ATOS) Earnings Per Share (EPS)?
The trailing EPS is -$4.69, and the forward EPS is -$4.38.
What is Atossa Therapeutics, Inc (ATOS) EBITDA?
Atossa Therapeutics, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -8.49 million.
Does Atossa Therapeutics, Inc (ATOS) pay dividends?
No. Atossa Therapeutics, Inc does not pay a dividend.
What is Atossa Therapeutics, Inc (ATOS) beta (volatility) score?
Atossa Therapeutics, Inc has a beta of 1.246, suggesting it is more volatile than the market.
